Vascular proliferation is a prognostic factor in breast cancer

Breast Cancer Research and Treatment

Volumn 133, Issue 2, 2012, Pages 501-510

  Arnes, Jarle B ^a   Stefansson, Ingunn M ^a   Straume, Oddbjørn ^a   Baak, Jan P ^a,b,c   Lønning, Per E ^a,d   Foulkes, William D ^e,f,g   Akslen, Lars A ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b STAVANGER UNIVERSITY HOSPITAL   (Norway)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g MCGILL UNIVERSITY   (Canada)

Author keywords

Angiogenesis; Breast cancer; Prognosis; Vascular proliferation

Indexed keywords

BLOOD CLOTTING FACTOR 8; DOXORUBICIN; FLUOROURACIL; KI 67 ANTIGEN; MITOMYCIN;

ADULT; AGED; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL DENSITY; CELL PROLIFERATION; DISEASE ASSOCIATION; DISEASE MARKER; DISTANT METASTASIS; ENDOTHELIUM CELL; ETHNIC GROUP; FEMALE; FOLLOW UP; GENE MUTATION; HORMONAL THERAPY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; MICROVASCULATURE; ONCOGENE; PARTIAL MASTECTOMY; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; VASCULAR ENDOTHELIUM;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; ENDOTHELIAL CELLS; FEMALE; HUMANS; MICROVESSELS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84863727766     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1785-7     Document Type: Article

References (41)

1. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182-1186
2. FDA (2004) FDA approves first angiogenesis inhibitor to treat colorectal cancer. US Food and Drug Administration. http://www.fda.gov/bbs/topics/NEWS/ 2004/NEW01027.html. Accessed 24 Oct 2008
3. FDA (2008) New approval for Bevacizumab (Avastin). US Food and Drug Administration. http://www.fda.gov/cder/Offices/OODP/whatsnew/bevacizumab200802. htm. Accessed 24 Oct 2008
4. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bev-acizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666-2676. doi:10.1056/NEJMoa072113
5. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28(20):3239-3247. doi:10.1200/JCO. 2008.21.6457
6. Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Li-patov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29(10):1252-1260. doi:10.1200/JCO. 2010.28.0982
7. D'Agostino RB Sr (2011) Changing end points in breast-cancer drug approval-the Avastin story. N Engl J Med 365(2):e2. doi: 10.1056/NEJMp1106984
8. Couzin-Frankel J, Ogale Y (2011) FDA. Once on ''fast track, '' avastin now derailed. Science 333(6039):143-144. doi:10.1126/science.333.6039.143
9. Ratner M (2011) FDA panel votes to pull Avastin in breast cancer, again. Nat Biotechnol 29(8):676. doi:10.1038/nbt0811-676c
10. NCI (2008) Clinical Trials Search. National Cancer Institute. http://www.cancer.gov/search/ResultsClinicalTrials.aspx?proto colsearchid=4586362&sort=4&page=1&batchsize=10#. Accessed Oct 24 2008
11. Brem S, Cotran R, Folkman J (1972) Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 48(2):347-356
12. Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324(1):1-8
13. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G (1992) Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma [see comments]. J Natl Cancer Inst 84(24): 1875-1887
14. Rubin MA, Buyyounouski M, Bagiella E, Sharir S, Neugut A, Benson M, de la Taille A, Katz AE, Olsson CA, Ennis RD (1999) Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. Urology 53(3):542-547
15. Hlatky L, Hahnfeldt P, Folkman J (2002) Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94(12):883-893
16. Stefansson IM, Salvesen HB, Akslen LA (2006) Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res 66(6):3303-3309
17. Tavassoli F, Devillee PE (2003) World Health Organization classification of tumours, pathology and genetics of tumours of the breast and female genital organs, World Health Organization Monograph Series. IARC Press, Lyon
18. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histo-pathology 19(5):403-410
19. Baak JP, Gudlaugsson E, Skaland I, Guo LH, Klos J, Lende TH, Soiland H, Janssen EA, Zur Hausen A (2009) Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers. Breast Cancer Res Treat 115(2):241-254. doi:10.1007/s10549-008-0126-y
20. van Diest PJ, van der Wall E, Baak JP (2004) Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 57(7):675-681
21. Baak JP, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LV, Vermorken JB, Janssen EA (2005) Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol 23(25):5993-6001
22. Arnes JB, Brunet JS, Stefansson I, Begin LR, Wong N, Chappuis PO, Akslen LA, Foulkes WD (2005) Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res 11(11):4003-4011
23. Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Begin LR, Hamel N, Goffin JR, Wong N, Trudel M, Kapusta L, Porter P, Akslen LA (2004) The prognostic implication of the basal-like (cyclin E high/p27 low/p53?/ glomeruloid-micro-vascular-proliferation?) phenotype of BRCA1-related breast cancer. Cancer Res 64(3):830-835
24. Goffin JR, Straume O, Chappuis PO, Brunet JS, Begin LR, Hamel N, Wong N, Akslen LA, Foulkes WD (2003) Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer. Br J Cancer 89(6):1031-1034
25. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Borresen-Dale AL (2001) Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 61(6):2505-2512
26. Geisler S, Borresen-Dale AL, Johnsen H, Aas T, Geisler J, Ak-slen LA, Anker G, Lonning PE (2003) TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 9(15):5582-5588
27. DAKO Dako website (home). http://www.dako.com
28. Straume O, Chappuis PO, Salvesen HB, Halvorsen OJ, Haukaas SA, Goffin JR, Begin LR, Foulkes WD, Akslen LA (2002) Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers. Cancer Res 62(23):6808-6811
29. Weidner N (2004) The importance of tumor angiogenesis: the evidence continues to grow. Am J Clin Pathol 122(5):675-677
30. Sharma S, Sharma MC, Sarkar C (2005) Morphology of angio-genesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis. Histopathology 46(5):481-489
31. Uzzan B, Nicolas P, Cucherat M, Perret GY (2004) Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 64(9):2941-2955
32. Straume O, Salvesen HB, Akslen LA (1999) Angiogenesis is prognostically important in vertical growth phase melanomas. Int J Oncol 15(3):595-599
33. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacon JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF (2011) A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305(18):1873-1881. doi:10.1001/jama.2011.593
34. Fox SB, Gatter KC, Bicknell R, Going JJ, Stanton P, Cooke TG, Harris AL (1993) Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res 53(18): 4161-4163
35. Vartanian RK, Weidner N (1994) Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am J Pathol 144(6):1188-1194
36. Vartanian RK, Weidner N (1995) Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia: correlation with Gleason's score, microvessel density, and epithelial cell proliferation. Lab Invest 73(6):844-850
37. Vermeulen PB, Verhoeven D, Hubens G, Van Marck E, Go-ovaerts G, Huyghe M, De Bruijn EA, Van Oosterom AT, Dirix LY (1995) Microvessel density, endothelial cell proliferation and tumour cell proliferation in human colorectal adenocarcinomas. Ann Oncol 6(1):59-64
38. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG (2000) Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangio-genic tumor therapies. Cancer Res 60(5):1388-1393
39. Hillen F, van de Winkel A, Creytens D, Vermeulen AH, Griffioen AW (2006) Proliferating endothelial cells, but not microvessel density, are a prognostic parameter in human cutaneous melanoma. Melanoma Res 16(5):453-457
40. Hayes DF, Isaacs C, Stearns V (2001) Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia 6(4):375-392
41. Gasparini G (2001) Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. Crit Rev Oncol Hematol 37(2):97-114